source
- Sellas Life Sciences reports Phase 3 success for AML vaccine galinpepimut-SSellas Life Sciences announced on Tuesday that its experimental cancer vaccine achieved a positive outcome in a Phase 3 study. The trial enrolled patients with a specific form of acute myeloid leu…
- FDA flags VEGF safety concern in Summit Therapeutics' rejected bispecific cancer drug ivonescimabThe U.S. Food and Drug Administration identified a potential safety issue while reviewing ivonescimab, a bispecific cancer therapy being developed by Summit Therapeutics and Akeso. The agency’s co…